2017.06.03 Taiwan 5 biotechs to watch special report

  • 22
  • May

2017.05.22 First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia

Taipei, Taiwan, May 22, 2017 SyneuRx International (Taiwan) Corp. today announced that the first five subjects have been randomized for the company’s SND12 Phase IIb/III clinical trial. The trial will study the efficacy and safety of one of its leading investigational therapies, Clozaben®, for adult subjects with schizophrenia who are refractory to current treatments available. […]
  • 11
  • May

2017.05.11 First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial

Taipei, Taiwan, May 11, 2017 SyneuRx International (Taiwan) Corp. today announced that the first three subjects have been randomized from the 11 subjects screened into the company’s SND13 Phase IIb/III clinical trial within a short period of time.  The trial will study the efficacy and safety of its leading investigational therapy NaBen© for adult subjects […]